Alivexis, Inc. (“Alivexis”), a preclinical-stage computation-driven drug discovery company, will present our recent data from MOD-D, one of our drug discovery programs, at the 85^th Annual Meeting of the Japanese Cancer Association, to be held September 24th-26th in Kyoto, Japan.

Our presentation will focus on the pharmacological profile of AL003626, Alivexis’ highly potent novel WDR5 inhibitor, and its therapeutic activity in various MYC-driven cancers, in the session entitled “Novel Therapeutic Strategies Targeting Cancer Vulnerabilities”.

Alivexis’ presentation details are as follows:
Title: Development of AL003626, a Novel WDR5 Inhibitor Targeting the WDR5–MYC Axis for the Treatment of MYC-Driven Cancers
Presentation Number: E-1063
Authers: Masahiro Matsuki, Takafumi Shimizu, Taisuke Takahashi, Blake Mertz, William Sinko, and Yoh Terada
Presentation Date/Time: Thursday, September 24th, 12:50-14:05 (JST)
Venue: Kyoto International Conference Center, Room 12 (2F Room J)

Alivexis to Present MOD-D Program at the 85^th Annual Meeting of the Japanese Cancer Association(PDF)